International Consensus Guidance for Management of Myasthenia Gravis
Narayanaswami, Pushpa (Beth Israel Deaconess Medical Center/Harvard Medical School)
Sanders, Donald B. (Boston, MA; Department of Neurology)
Wolfe, Gil (Duke University Medical Center, Durham, NC; Department of Neurology)
Benatar, Michael (Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo, NY; Department of Neurology)
Cea, Gabriel (University of Miami, Miller School of Medicine. Miami, FL)
Evoli, Amelia (Dipartimento di Neuroscienze, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy)
Gilhus, Nils Erik (Department of Clinical Medicine, University of Bergen, Norway)
Illa, Isabel (Institut d'Investigació Biomèdica Sant Pau)
Kuntz, Nancy L. (Departments of Pediatrics and Neurology, Northwestern Feinberg School of Medicine, Chicago, IL)
Massey, Janice (Boston, MA; Department of Neurology)
Melms, Arthur (Neurology, University of Tübingen Medical Centre, Tübingen, Germany)
Murai, Hiroyuki (Department of Neurology, International University of Health and Welfare, Narita, Japan)
Nicolle, Michael (Department of Clinical Neurological Sciences, Western University, London, ON, Canada)
Palace, Jacqueline (John Radcliffe Hospital (Oxford, Regne Unit))
Richman, David (department of Neurology, University of California, Davis, Davis, CA)
Verschuuren, Jan (Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands)
Universitat Autònoma de Barcelona

Fecha:	2021
Resumen:	To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with the addition of one member to represent South America. All previous recommendations were reviewed for currency, and new consensus recommendations were developed on topics that required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous e-mail votes were used to reach consensus, with modifications to recommendations between rounds based on the panel input. A simple majority vote (80% of panel members voting "yes") was used to approve minor changes in grammar and syntax to improve clarity. The previous recommendations for thymectomy were updated. New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment. This updated formal consensus guidance of international MG experts, based on new evidence, provides recommendations to clinicians caring for patients with MG worldwide.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article de revisió ; Article ; Versió publicada
Publicado en:	Neurology, Vol. 96 (january 2021) , p. 114-122, ISSN 1526-632X

DOI: 10.1212/WNL.0000000000011124
PMID: 33144515

9 p, 147.5 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos publicados